Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Mitochondrial dysfunction is linked to Parkinson's disease (PD).
• The precise connection between mitochondrial impairment and α-synuclein pathology in PD remains unclear.
• Understanding this link is crucial for developing effective PD therapies.

Purpose of the Study:

• To investigate the role of intramitochondrial protein homeostasis in α-synuclein aggregation.
• To determine if specific mitochondrial stressors influence α-synuclein pathology.
• To explore potential therapeutic strategies targeting mitochondrial function in PD.

Main Methods:

• Utilized specific mitochondrial inhibitors and electron microscopy (EM).
• Performed biochemical assays to assess protein aggregation and mitochondrial function.
• Investigated the impact of altered mitochondrial proteases and protein import on α-synuclein.

Main Results:

• Interference with intramitochondrial proteases (HtrA2, Lon) and protein import exacerbated α-synuclein seeding.
• Direct inhibition of mitochondrial complex I, increased calcium, or reactive oxygen species did not affect α-synuclein pathology.
• Similar mechanisms were observed for amyloid-β 1-42 (Aβ42) aggregation.

Conclusions:

• Intramitochondrial protein homeostasis significantly influences the aggregation of cytosolic proteins like α-synuclein.
• Mitochondria play a direct role in cytosolic protein quality control.
• Therapeutic strategies should focus on maintaining mitochondrial fitness rather than solely targeting downstream dysfunction for PD treatment.